Pure Global

Study of STP938 in Advanced Solid Tumours - Trial NCT06297525

Access comprehensive clinical trial information for NCT06297525 through Pure Global AI's free database. This Phase 1 trial is sponsored by Step Pharma, SAS and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06297525
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06297525
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study of STP938 in Advanced Solid Tumours
An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

Study Focus

Solid Tumor

STP938

Interventional

drug

Sponsor & Location

Step Pharma, SAS

Timeline & Enrollment

Phase 1

Sep 01, 2024

May 01, 2027

70 participants

Primary Outcome

Safety and Tolerability

Summary

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy.
 
 The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

ICD-10 Classifications

Malignant neoplasm: Connective and soft tissue, unspecified
Carcinoma in situ, unspecified
Malignant neoplasm: Parametrium
Malignant neoplasm of other connective and soft tissue
Malignant neoplasm: Lip, unspecified, inner aspect

Data Source

ClinicalTrials.gov

NCT06297525

Non-Device Trial